CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 22 oral and poster presentations at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2015 in Chicago.
“Since Foundation Medicine launched its flagship product, FoundationOne®, at ASCO three years ago, we have continued to provide high-quality, high-impact data to support and advance the transformation of cancer care,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “This year, much of our data focuses on tumors that remain therapeutic challenges such as non-small cell lung cancer and others that are similarly arduous but under studied, including biliary tract and AYA malignancies. We believe our data demonstrate the power of molecular information in guiding identification, characterization and treatment of difficult cancers, and ultimately, accelerating precision medicine and better outcomes in cancer care.”
The company's molecular information products, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at ASCO provide further evidence of the clinical utility of Foundation Medicine's comprehensive genomic profiles to identify the molecular alterations in patient’s cancer and aid in the development of targeted therapies.
The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:
Date & Time: Sunday, May 31, 2015 from 4:30-4:42 p.m. CT
Title:
Comprehensive genomic profiling of biliary tract cancers to reveal
tumor-specific difference and frequency of clinically relevant genomic
alterations
Abstract: 4009
Location: E Hall D2
Session:
To Lump or To Split: Molecular, Anatomic, and Etiologic Subtyping of
Noncolorectal Gastrointestinal Malignancies and Potential Therapeutic
Implications
Presenter: Milind Javle, M.D., The University
of Texas MD Anderson Cancer Center
Collaborators: Albany
Medical College, The University of Texas MD Anderson Cancer Center,
University of Chicago
Date & Time: Monday, June 1, 2015 from 10:24-10:36 a.m. CT
Title:
Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian
cancer patients likely to respond to rucaparib using tumor genetic
analysis
Abstract: 5508
Location: E354b
Session:
Gynecological Cancer
Presenter: Iain A. McNeish,
Ph.D., Institute of Cancer Sciences, University of Glasgow
Collaborators:
Institute of Cancer Sciences – University of Glasgow, Princess Margaret
Cancer Centre, The University of Texas MD Anderson Cancer Center, Royal
Melbourne Hospital, University of California – Los Angeles, British
Columbia Cancer Agency, The Ohio State University College of Medicine,
Cancer Research UK Cambridge Institute, University College London Cancer
Institute, Memorial Sloan Kettering Cancer Center, Vall d’Hebron
University Hospital, Institut Gustave Roussy, Clovis Oncology,
University of Washington School of Medicine
Date & Time: Monday, June 1, 2015 from 5:12-5:24 p.m. CT
Title:
Comprehensive genomic profiling (CGP) of advanced cancers to
identify MET exon 14 alterations that confer sensitivity to MET
inhibitors
Abstract: 11007
Location: E450
Session:
Tumor Biology
Presenter: Sai-Hong Ignatius Ou, M.D.,
Ph.D., University of California Irvine
Collaborators:
University of California at Los Angeles, University of North Carolina at
Chapel Hill, Michiana Hematology Oncology PC, University of Chicago,
University of Miami Sylvester Comprehensive Cancer Center, Texas
Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Albany Medical College, University of California Irvine Health Chao
Family Comprehensive Cancer Center
The schedule for poster discussions and poster presentations by Foundation Medicine and/or its collaborators is as follows:
Poster Display: Sunday, May 31, 2015 from 8:00 a.m.-12:45 p.m. CT
Poster
Presentation: Sunday, May 31, 2015 from 11:30 a.m.-12:45 p.m. CT
Title:
Prospective study comparing outcomes in patients with advances
malignancies on molecular alteration-matched versus non-matched therapy
Abstract:
11019
Poster Board: 231
Poster Display Location:
S Hall A
Poster Presentation Location: S406
Session: Tumor
Biology
Presenter: Jennifer J. Wheler, M.D., The University
of Texas MD Anderson Cancer Center
Collaborators: The
University of Texas MD Anderson Cancer Center, Department of
Investigational Therapeutics (Phase 1 Program) - Sarah Cannon Research
Institute at HealthOne, University of California San Diego
Poster Display: Sunday, May 31, 2015 from 8:00-11:30 a.m. CT
Poster
Discussion: Sunday, May 31, 2015 from 11:30 a.m.-12:45 p.m. CT
Title:
Comprehensive genomic profiling of sarcomas from 267 adolescents and
young adults to reveal a spectrum of targetable genomic alterations
Abstract:
11020
Poster Board: 232
Poster Display Location: S
Hall A
Poster Discussion Location: S406
Session: Tumor
Biology
Presenter: Deborah Morosini, M.D., vice
president, clinical development, Foundation Medicine
Collaborators:
Albany Medical College, Oregon Health and Science University
Poster Display: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Poster
Discussion: Monday, June 1, 2015 from 4:45-6:00 p.m. CT
Title:
Defects in DNA repair genes and sensitivity to cisplatin based
neoadjunctive chemotherapy (NAC) for bladder cancer
Abstract: 4514
Poster
Board: 184
Poster Display Location: S Hall A
Poster
Discussion Location: E Arie Crown Theatre
Session: Genitourinary
(Nonprostate) Cancer
Presenter: Yu-Ning Wong, M.D., Fox
Chase Cancer Center
Collaborators: Fox Chase Cancer Center,
Temple University Health System, The Sidney Kimmel Cancer Center at
Thomas Jefferson University
Poster Display: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Poster
Discussion: Monday, June 1, 2015 from 4:45-6:00 p.m. CT
Title:
Comprehensive genomic profiling of 443 patients with advanced renal
cell carcinoma (RCC) to reveal clinically relevant genomic alterations
and to aid in classification of rare subtypes
Abstract: 4520
Poster
Board: 190
Poster Display Location: S Hall A
Poster
Discussion Location: E Arie Crown Theatre
Session: Genitourinary
(Nonprostate) Cancer
Presenter: Sumanta Kumar Pal, M.D.,
City of Hope
Collaborators: City of Hope, The University of
Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Oncology
Service and Oncology Research Unit – HSL/PUCRS
Date & Time: Saturday, May 30, 2015 from 1:15-4:45 p.m. CT
Title:
Awaiting Comprehensive genomic profiling of cervical squamous
cell carcinoma to identify targeted therapy options
Abstract: 5602
Poster
Board: 160
Location: S Hall A
Session: Gynecological
Cancer
Presenter: Julia Andrea Elvin, M.D., Ph.D.,
pathologist, Foundation Medicine
Collaborators: Northwestern
University, Sarah Cannon Research Institute, Northwestern Medicine
Developmental Therapeutics Institute, Albany Medical College, Stanford
University
Date & Time: Saturday, May 30, 2015 from 1:15-4:45 p.m. CT
Title:
Comprehensive genomic profiling of salivary gland adenocarcinomas to
reveal a high frequency of druggable targets
Abstract: 6040
Poster
Board: 363
Location: S Hall A
Session: Head
and Neck Cancer
Presenter: Matthew J. Hawryluk,
Ph.D., vice president, corporate and business development, Foundation
Medicine
Collaborator: Albany Medical College
Date & Time: Sunday, May 31, 2015 from 8:00-11:30 a.m. CT
Title:
Germline variants in cancer risk genes detected by NGS-based
comprehensive tumor genomic profiling (CGP)
Abstract: 11084
Poster
Board: 298
Location: S Hall A
Session: Tumor
Biology
Presenter: Michael J. Hall, M.D., Fox Chase Cancer
Center
Collaborator: Fox Chase Cancer Center
Date & Time: Sunday, May 31, 2015 from 8:00-11:30 a.m. CT
Title:
Genomics of young lung cancer study
Abstract: TPS11110
Poster
Board: 324b
Location: S Hall A
Session: Tumor
Biology
Presenter: Barbara J. Gitlitz, M.D.,
University of Southern California Keck School of Medicine
Collaborators:
University of Southern California Keck School of Medicine, Addario
Lung Cancer Medical Institute, Dana-Farber Cancer Institute
Date & Time: Monday, June 1, 2015 from 8:00-11:30 a.m. CT
Title:
Comprehensive genomic profiling of anal squamous cell carcinoma to
reveal frequency of clinically relevant genomic alterations in the
PI3K/mTOR pathway
Abstract: 3522
Poster Board: 14
Location:
S Hall
Session: Gastrointestinal (Colorectal) Cancer
Presenter:
Eric M. Sanford, senior research associate, Foundation Medicine
Collaborator:
Albany Medical College
Date & Time: Monday, June 1, 2015 from 8:00-11:30 a.m. CT
Title:
Comprehensive genomic profiling of clinically advanced colorectal
carcinoma to reveal frequent opportunities for targeted therapies
Abstract:
3553
Poster Board: 45
Location: S Hall A
Session:
Gastrointestinal (Colorectal) Cancer
Presenter: Jeffrey
S. Ross, M.D., medical director, Foundation Medicine
Collaborator:
Albany Medical College
Date & Time: Monday, June 1 2015 from 8:00-11:30 a.m. CT
Title:
Genomic analysis of colitis-associated cancers
Abstract: 3566
Poster
Board: 58
Location: S Hall A
Session: Gastrointestinal
(Colorectal) Cancer
Presenter: Rona D. Yaeger, M.D.,
Memorial Sloan Kettering Cancer Center
Collaborators: Memorial
Sloan Kettering Cancer Center, The Children’s Hospital of Philadelphia
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Analysis of BRAF alterations and molecular profiling in glioblastoma
and astrocytoma
Abstract: 2074
Poster Board: 64
Location:
S Hall A
Session: Central Nervous System Tumors
Presenter:
Nadia Faiq, University of California San Diego
Collaborator: University
of California San Diego Moores Cancer Center
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Comprehensive genomic profiling of rare tumors in dedicated
community clinic
Abstract: 6540
Poster Board: 97
Locations:
S Hall
Presenter: William Jeffrey Edenfield, M.D.,
Greenville Health System
Collaborator: Institute for
Translational Oncology Research – Greenville Health System
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Prospective clinical study of precision oncology in solid tumors
Abstract:
6585
Poster Board: 142
Location: S Hall A
Presenter:
Davendra Sohal, M.D., Cleveland Clinic
Collaborators:
Cleveland Clinic Taussig Cancer Institute, University of Virginia School
of Medicine, University of Illinois Chicago
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Comprehensive genomic profiling of 295 cases of clinically advanced
urothelial carcinoma of the urinary bladder to reveal frequency of
clinically relevant genomic alterations
Abstract: 4526
Poster
Board: 196
Location: S Hall A
Session: Genitourinary
(Nonprostate) Cancer
Presenter: Matthew J. Hawryluk,
Ph.D., vice president, corporate and business development, Foundation
Medicine
Collaborators: The Urological Institute of
Northeastern New York, Albany Medical Center, Albany Medical College
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Amplification of CRKL in human cancer: A rare event associated with
potential sensitivity to targeted therapy
Abstract: 1526
Poster
Board: 350
Location: S Hall A
Session: Cancer
Prevention, Genetics, and Epidemiology
Presenter: Kai Wang,
M.D., Ph.D., senior scientist, technical supervisor, clinical next
generation sequencing, Foundation Medicine
Collaborators:
Huntsman Cancer Institute – University of Utah, Albany Medical College
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Comprehensive genomic profiling of advanced stage esophageal
squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC)
Abstract:
1535
Poster Board: 359
Location: S Hall A
Session:
Cancer Prevention, Genetics, and Epidemiology
Presenter: Kai
Wang, M.D., Ph.D., senior scientist, technical supervisor, Foundation
Medicine
Collaborator: Albany Medical College
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Intratumoral heterogeneity of cancer driver genomic alterations
across several tumor types
Abstract: 1558
Poster
Board: 382
Location: S Hall A
Session: Cancer
Prevention, Genetic, and Epidemiology
Presenter: Kai Wang,
M.D., Ph.D., senior scientist, technical supervisor, Foundation Medicine
Collaborator:
Albany Medical College
Date & Time: Monday, June 1, 2015 from 1:15-4:45 p.m. CT
Title:
Hereditary implications of somatic tumor testing
Abstract: 1523
Poster
Board: 347
Location: S Hall A
Presenter: Pauline
Funchain, M.D., Cleveland Clinic
Collaborators: Cleveland
Clinic Taussig Cancer Institute, University of Virginia School of
Medicine
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of molecular information to guide identification, characterization and treatment of cancer, including difficult cancers; the ability of comprehensive genomic profiling, including FoundationOne and FoundationOne Heme, to identify genomic alterations and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that FoundationOne and Foundation Medicine's molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
